Hepatitis C Therapy - How Hepatitis C virus highjack protein synthesis machinery in humans

How Hepatitis C virus highjack protein synthesis machinery in humans
RxPG News - This new information also helps to explain how viruses, such as Hepatitis C, are able to highjack protein synthesis machinery in humans for their own purposes. 10:14:49 HCV Channel subscribe to HCV newsletter Latest Research : Infectious Diseases : HCV COMMENT | EMAIL | PRINT How

MIGENIX initiates enrolment in Phase IIb HCV study of celgosivir+Pegetron
InPharm.com - Celgosivir is a first-in-class, orally-administered, alpha glucosidase 1 inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. Results of the study are anticipated in mid-2006.

Increased Incidence of Stopping HAART Due to Toxicity or Patient/Physician Choice in Patients with HIV-HCV Coi
HIV and Hepatitis.com - While there are conflicting data in the medical literature concerning the risk factors for vertical transmission of HCV, the two studies reviewed here share many more similarities in their conclusions than differences. HIV-HCV Coinfection Main Page Treatment for HIV-HCV Coinfection Feature Articles Treatment Guidelines

Positive phase I trial for Schering-Plough HCV treatment
Datamonitor - Currently, there are no products approved for treating HCV patients who failed previous therapies, representing an area of great unmet medical need. alfa-2b).Hepatitis C virus (HCV) genotype 1 is the most common